Strata Skin Sciences (NASDAQ: SSKN) and Ekso Bionics Holdings (NASDAQ:EKSO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.
This is a breakdown of current recommendations for Strata Skin Sciences and Ekso Bionics Holdings, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Strata Skin Sciences||0||0||2||0||3.00|
|Ekso Bionics Holdings||0||0||2||0||3.00|
Strata Skin Sciences currently has a consensus target price of $12.00, indicating a potential upside of 605.88%. Ekso Bionics Holdings has a consensus target price of $6.00, indicating a potential upside of 421.74%. Given Strata Skin Sciences’ higher probable upside, research analysts plainly believe Strata Skin Sciences is more favorable than Ekso Bionics Holdings.
Valuation & Earnings
This table compares Strata Skin Sciences and Ekso Bionics Holdings’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Strata Skin Sciences||$32.37 million||0.13||$5.87 million||($2.70)||-0.63|
|Ekso Bionics Holdings||$7.49 million||3.96||-$27.14 million||($1.55)||-0.74|
Strata Skin Sciences has higher revenue and earnings than Ekso Bionics Holdings. Ekso Bionics Holdings is trading at a lower price-to-earnings ratio than Strata Skin Sciences, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Strata Skin Sciences has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Comparatively, Ekso Bionics Holdings has a beta of -0.86, suggesting that its share price is 186% less volatile than the S&P 500.
This table compares Strata Skin Sciences and Ekso Bionics Holdings’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Strata Skin Sciences||-18.00%||-41.58%||-13.22%|
|Ekso Bionics Holdings||-372.20%||-798.93%||-146.30%|
Insider and Institutional Ownership
24.1% of Strata Skin Sciences shares are held by institutional investors. Comparatively, 6.0% of Ekso Bionics Holdings shares are held by institutional investors. 12.9% of Strata Skin Sciences shares are held by insiders. Comparatively, 7.1% of Ekso Bionics Holdings shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Strata Skin Sciences beats Ekso Bionics Holdings on 9 of the 11 factors compared between the two stocks.
Strata Skin Sciences Company Profile
STRATA Skin Sciences, Inc., formerly MELA Sciences, Inc., is a medical technology company. The Company is engaged in developing and commercializing products for the diagnosis and treatment of dermatological disorders. The Company has three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment and Dermatology Imaging. The XTRAC and VTRAC products are the devices used for the treatment of psoriasis, vitiligo and other skin disorders. The XTRAC system delivers targeted ultraviolet light to affected areas of skin, leading to psoriasis clearing and vitiligo repigmentation, following a series of treatments. The Company’s technology includes XTRAC Excimer Laser, VTRAC Lamp and MelaFind. MelaFind is a non-invasive, point-of-care instrument to aid dermatologists in their decision to biopsy suspicious pigmented lesions, such as melanoma. The Company has approximately two distribution channels for phototherapy treatment equipment.
Ekso Bionics Holdings Company Profile
Ekso Bionics Holdings, Inc. designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness. The companys Ekso device is primarily used in a clinic or rehabilitation setting. It also performs research and development work on human exoskeletons and related technologies. The company has a license agreement with Lockheed Martin Corporation to develop products for military applications, as well as with OttoBock Healthcare Products Gmbh. The company was founded in 2005 and is headquartered in Richmond, California. Ekso Bionics Holdings, Inc. operates as a subsidiary of Magee Rehabilitation Hospital.
Receive News & Ratings for Strata Skin Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strata Skin Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.